206 related articles for article (PubMed ID: 8277097)
1. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction.
Purvis JA; McNeill AJ; Siddiqui RA; Roberts MJ; McClements BM; McEneaney D; Campbell NP; Khan MM; Webb SW; Wilson CM
J Am Coll Cardiol; 1994 Jan; 23(1):6-10. PubMed ID: 8277097
[TBL] [Abstract][Full Text] [Related]
2. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
[TBL] [Abstract][Full Text] [Related]
3. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study.
Verheugt FW; Liem A; Zijlstra F; Marsh RC; Veen G; Bronzwaer JG
J Am Coll Cardiol; 1998 Feb; 31(2):289-93. PubMed ID: 9462569
[TBL] [Abstract][Full Text] [Related]
4. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
[TBL] [Abstract][Full Text] [Related]
5. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
[TBL] [Abstract][Full Text] [Related]
7. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
[TBL] [Abstract][Full Text] [Related]
8. Patency trials with reteplase (r-PA): what do they tell us?
Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
[TBL] [Abstract][Full Text] [Related]
9. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
[TBL] [Abstract][Full Text] [Related]
10. ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
Malcolm AD; Keltai M; Walsh MJ
Eur Heart J; 1996 Oct; 17(10):1522-31. PubMed ID: 8909909
[TBL] [Abstract][Full Text] [Related]
11. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS).
Neuhaus KL; von Essen R; Tebbe U; Vogt A; Roth M; Riess M; Niederer W; Forycki F; Wirtzfeld A; Maeurer W
J Am Coll Cardiol; 1992 Apr; 19(5):885-91. PubMed ID: 1552106
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
[TBL] [Abstract][Full Text] [Related]
13. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK).
Neuhaus KL; von Essen R; Vogt A; Tebbe U; Rustige J; Wagner HJ; Appel KF; Stienen U; König R; Meyer-Sabellek W
J Am Coll Cardiol; 1994 Jul; 24(1):55-60. PubMed ID: 8006283
[TBL] [Abstract][Full Text] [Related]
14. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
Arnout J; Simoons M; de Bono D; Rapold HJ; Collen D; Verstraete M
J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of double bolus alteplase in the treatment of acute myocardial infarction.
Purvis JA; Trouton TG; Roberts MJ; McKeown P; Mulholland MG; Dalzell GW; Wilson CM; Patterson GC; Webb SW; Khan MM
Am J Cardiol; 1991 Dec; 68(17):1570-4. PubMed ID: 1746456
[TBL] [Abstract][Full Text] [Related]
16. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
Lundergan CF; Reiner JS; McCarthy WF; Coyne KS; Califf RM; Ross AM
J Am Coll Cardiol; 1998 Sep; 32(3):641-7. PubMed ID: 9741505
[TBL] [Abstract][Full Text] [Related]
17. Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction.
Tranchesi B; Chamone DF; Cobbaert C; Van de Werf F; Vanhove P; Verstraete M
Am J Cardiol; 1991 Jul; 68(2):161-5. PubMed ID: 1829574
[TBL] [Abstract][Full Text] [Related]
18. HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte.
von Essen R; Zeymer U; Tebbe U; Jessel A; Kwasny H; Mateblowski M; Niederer W; Wagner J; Mäurer W; von Leitner ER; Haerten K; Roth M; Neuhaus KL
Coron Artery Dis; 1998; 9(5):265-72. PubMed ID: 9710686
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of a single intravenous bolus injection of tissue-type plasminogen activator in acute myocardial infarction. Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST) Investigators.
Hackett D; Andreotti F; Haider AW; Brunelli C; Shahi M; Fussell A; Buller N; Foale R; Lipkin D; Caponnetto S
Am J Cardiol; 1992 Jun; 69(17):1393-8. PubMed ID: 1590225
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
Wallentin L; Bergstrand L; Dellborg M; Fellenius C; Granger CB; Lindahl B; Lins LE; Nilsson T; Pehrsson K; Siegbahn A; Swahn E
Eur Heart J; 2003 May; 24(10):897-908. PubMed ID: 12714021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
